Thiazole-lactam-spiroheterocyclic compounds and applications thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound as represented by formula (I) and pharmaceutically acceptable salts thereof.

##STR00001##

Thiazole-lactam-spiroheterocyclic compounds and applications thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound as represented by formula (I) and pharmaceutically acceptable salts thereof.

##STR00001##

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

The present embodiments provide compounds of Formula I, pharmaceutical compositions of the compounds, and methods for treating diseases such as cancer.

##STR00001##

Described herein are compounds of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Described herein are compounds of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.